Smoking substitute system

Abstract

A consumable for a smoking substitute device contains a liquid aerosol-forming substrate, wherein the substrate comprises an infusion of solid tobacco-derived material in aerosol-former solution, and the infusion is combined with a nicotine formulation. The nicotine formulation may comprise a nicotine salt, particularly nicotine lactate. The substrate is obtained by macerating solid tobacco-derived material in aerosol-former liquid to form an infusion of solid tobacco-derived material and combining the infusion with a nicotine formulation. The tobacco-derived solids are macerated for a time period sufficient for the infusion to undergo a required change in physical characteristics (such as color or viscosity) or a required change in chemical characteristics (such as amount of nicotine release). Tobacco-derived solid may be visible in the substrate as an indicator that it is not a pharmaceutical product.

What is claimed is: 
     
         1 . A consumable for a smoking substitute device containing a liquid aerosol-forming substrate, wherein the liquid aerosol-forming substrate comprises an infusion of solid tobacco-derived material in aerosol-former solution, and the infusion is combined with a nicotine formulation. 
     
     
         2 . A consumable according to  claim 1 , wherein the infusion for the liquid aerosol-forming substrate comprises a suspension of solid tobacco-derived material saturated with aerosol-former. 
     
     
         3 . A consumable according to any preceding claim, wherein the infusion for the liquid aerosol-forming substrate contains nicotine-containing components released from the solid tobacco-derived material. 
     
     
         4 . A consumable according to any preceding claim, wherein the infusion for the liquid aerosol-forming substrate is obtainable by macerating solid tobacco-derived material in aerosol-former solution. 
     
     
         5 . A consumable according to any preceding claim, wherein the nicotine formulation contains free-base nicotine. 
     
     
         6 . A consumable according to any preceding claim, wherein the nicotine formulation contains a nicotine salt. 
     
     
         7 . A consumable according to any preceding claim, wherein the nicotine formulation contains (i) a nicotine salt of an organic acid and/or (ii) a mono-protonated nicotine salt. 
     
     
         8 . A consumable according to any preceding claim, wherein the nicotine formulation contains a nicotine salt of an organic acid selected from one or more of lactic acid, benzoic acid, formic acid, acetic acid, butyric acid, citric acid, levulinic acid, oleic acid, oxalic acid, propionic acid, phenylacetic acid, pyruvic acid, salicylic acid, sorbic acid, succinic acid and tartaric acid. 
     
     
         9 . A consumable according to  claim 8 , wherein the nicotine formulation contains a nicotine salt of lactic acid. 
     
     
         10 . A consumable according to any preceding claim, wherein (i) the nicotine formulation provides at least 50 wt % of the total nicotine content of the liquid aerosol-forming substrate and/or (ii) the liquid aerosol-forming substrate contains at least 7.5 mg/ml of nicotine. 
     
     
         11 . A consumable according to any preceding claim, wherein the liquid-aerosol forming substrate comprises solid tobacco-derived material corresponding to the sieve fraction of between 100 to 1000 μm. 
     
     
         12 . Use of a liquid aerosol-forming substrate as defined in any one of  claims 1  to  11  in the manufacture of a consumable for a smoking substitute device for vaping e-liquid. 
     
     
         13 . A method for manufacturing a consumable for a smoking substitute device which contains a liquid aerosol-forming substrate as defined in any one of  claims 1  to  11 , which method comprises combining solid tobacco-derived material and aerosol former liquid to form an infusion of solid tobacco-derived material in aerosol-former solution, and combining the infusion with a nicotine formulation. 
     
     
         14 . A method according to  claim 13 , which comprises macerating solid tobacco-derived material in aerosol-former solution for a time period sufficient for the infusion to undergo a required change in physical and/or chemical characteristics. 
     
     
         15 . A method according to  claim 13  or  14 , which comprises a step of determining the nicotine content of the infusion and subsequently combining the infusion with a nicotine formulation in an amount appropriate to provide a liquid aerosol-forming substrate having a predetermined nicotine content. 
     
     
         16 . A vaping smoking substitute device configured for vaping a liquid aerosol-forming substrate as defined in any one of  claims 1  to  11 .